Here is the big move. From the press release about it's highlighted presentation at the Conference of Association of Practicing Pathologists (APPI) there is new info. Not too many people notice this kind of thing. Maybe a few do and are buying stock. Below is an example of how combined the power of ERB is so large and formidable. Market cap should be much higher IMO.
"Incepted in the year 1979, Transasia Bio-Medicals Ltd (transasia.co.in) is headquartered in Mumbai, India. It is one of India’s largest In-vitro Diagnostics Company and offers solutions and products in Biochemistry, Hematology, Coagulation, ESR, Immunology, Urinalysis, Critical Care, Electrophoresis, Molecular Diagnostics, Diabetes Management and Microbiology. Infact, Transasia is the first Indian company to manufacture and export sophisticated, state of the art blood analyzers and reagents.
Transasia is a part of the global ERBA Diagnostics Mannheim GmbH Group. The ERBA Group has spread its footprint across USA, Europe, Turkey and Eastern Europe, Russia and France, by means of various acquisitions ERBA Lachema s.r.o.(Czech Republic), ERBA Russia (Russia), ERBA Diagnostics, Inc. (USA), Diamedix Corporation (USA), Delta Biologicals, S.r.l (Italy), ImmunoVision, Inc. (USA), Erba DDS (Turkey), ERBA Diagnostics France (France), JAS Diagnostics Inc. (USA) and Drew Scientific (USA).
Transasia manufactures and markets equipment and reagents, with an impressive install base of around 38,000 equipments across India. Transasia also exports to more than 94 countries in five continents.
The vast network of more than 150 service engineers, 350+ Sales and Marketing Team, 14 zonal offices, and 300+ Distributors allows us to reach out to customers across the length and breadth of the country.
Alliances with international partners like Sysmex Corporation (Japan), Medica (USA), Diesse (Italy), Immco (USA), Helena Bio-sciences (UK), Genprobe (USA)..."